74results about How to "Improve drug efficacy" patented technology

Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described:

The invention belongs to the technical field of medicines. The invention provides an injectable medicated particle-inlaid porous composite microsphere preparation. The injectable medicated particle-inlaid porous composite microsphere preparation is prepared by the following steps: wrapping polypeptide and protein medicines or chemical medicines by using hydrophilic materials such as chitosan, collagen or albumin to form medicine-loading particles; constructing microspheres with three-dimensional (3D) porous structures by using medicated particles and porous microsphere materials; and inlaying the medicated particles in the porous microspheres. The invention also provides a preparation method of the porous composite microsphere preparation and an application of the porous composite microsphere preparation in preparation of tissue defect repair materials. The porous composite microsphere preparation provided by the invention can realize slow release of the medicines and is favorable for proliferation and differentiation of seed cells.

The present invention is directed to attaching drugs and other functional groups to surfaces of nano-sized diamonds (NDs) to enhance the efficacy of drugs and other substances. The method involved enhancing the efficacy of a drug having an active site by acquiring a plurality of nanodiamond (ND) particles having a plurality of carbon chain surface molecules on its surface. Intermediate amine entities are covalently attached to the surface molecules of the ND particles. These are then replaces with said drug molecules such that the active sites of said drug molecules point away from the ND particle exposing them for enhanced activity and enhanced drug efficacy. The efficacy of antimicrobial drugs are enhanced, however, this may be used with many different types of drugs.

The invention belongs to the technical field of medicine, and provides a PLGA (poly(lactic-co-glycolic acid)) porous composite microsphere preparation embedded with BMP-2 and TGF-beta1 containing microspheres therein, which not only can bring about benefits for the adhesion and the growth of seed cells by virtue of a 3D porous structure but also can undergo controlled- and sustained-release and can be applied to injection. The invention also provides a preparation method of the porous composite microsphere preparation as well as application of the porous composite microsphere preparation in preparing bone or cartilage tissue defect repairing materials. The porous composite microsphere disclosed by the invention, which can serve as a good carrier for cell adhesion and proliferation and can be directly injected to a target part, can offer a possibility of non-surgical repair to bone and cartilage tissue injuries; and the porous composite microsphere preparation is extensive in clinical application and market prospect.

The invention discloses a preparation method and application of drug sustained-release carrier hydrogel, and belongs to the technical field of medical polymers. The preparation method comprises the following steps: firstly, synthesizing beta-cyclodextrin with a bisacrylamide group with a hydrophobic cavity structure by taking beta-cyclodextrin and acryloyl chloride as raw materials, then preparing methylacryloylated gelatin from gelatin and methacrylic anhydride, and then performing free radical copolymerization under 365nm ultraviolet light by taking Irgacure2959 as an initiator, thereby obtaining the hydrogel. The drug loading capacity of the drug carrier hydrogel can reach 40.86 mg/g, and the drug carrier hydrogel can be continuously released for more than 96 hours in different environments (normal in-vivo physiological environment, lesion site environment and simulated gastric juice environment). A drug sustained-release carrier hydrogel system prepared by the invention is safe and non-toxic, has solubilization on hydrophobic drugs, improves the medication efficiency, and broadens the application range of the hydrogel in the field of medicines.

The present invention provides a cyclic amide derivative useful as a drug for treating thrombosis, which is represented by the formula (I)-:

wherein R¹ represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent chain hydrocarbon group, a represents 0, 1, or 2, X¹ represents an optionally substituted lower alkylene or an optionally substituted lower alkenylene, Y¹ represents —C(O)—, —S(O)— or —S(O)₂—, A represents a piperazine ring which may be further substituted or a piperidine ring which may be further substituted, X² represents a bond or an optionally substituted lower alkylene, Y² represents —C(O)—, —S(O)—, —S(O)₂— or —C(═NR⁷)—, X³ represents an optionally substituted C_1-4 alkylene or an optionally substituted C_2-4 alkenylene, Z³ represents —N(R⁴)—, —O— or a bond, Z¹ represents —C(R²)(R^2′)—, —N(R²)—, etc., and Z² represents —C(R³)(R^3′)—, —N(R³)—, etc., or a salt thereof.

The present invention relates to a phenol derivative and the preparation method and use in medicine thereof, and particular to a phenol derivative represented by general formula (A) or a stereoisomer, a solvate, a metabolite, a prodrug, a pharmaceutically acceptable salt or a cocrystal thereof, a preparation method thereof, a pharmaceutical composition comprising the same, and use of the compound or composition of the present invention in the field of the central nervous system; wherein the definitions of substituents in general formula (A) are the same as those in the Description.

The invention belongs to the technical field of immunotherapy, and particularly relates to application of a hypoxia-adjustable promoter in CAR-T, a CAR structure of the hypoxia-adjustable promoter, anexpression vector, CAR-T cells, application of the CAR-T cells, a method for improving the IFN-gamma and/or IL-2 factor secretion capacity of the CAR-T cells in a hypoxia environment, and a method for improving the CAR-T cell killing capacity in the hypoxia environment. The CAR structure contains the hypoxia-adjustable promoter, the hypoxia-adjustable promoter is formed by connecting Hif1a adjusting elements and mini promoters, and the number of repetitions of the Hif1a adjusting elements is 3-5. The CAR structure induced and started by the hypoxia microenvironment not only can be effectivelyexpressed in T lymphocytes, but also can enhance the activation of the CAR-T cells in the hypoxia environment and enhance the effectiveness and safety of the CAR-T, and can be used for targeted therapy of tumors.

The invention belongs to the technical field of pharmacies, relates to a traditional Chinese medicine raw material extract and an extraction method thereof, particularly relates to a ginkgo leaf extract and an extraction method thereof. The extraction method for the extract comprises the following steps: smashing dried ginkgo leaves with a smashing machine; and performing reflux extraction on thesmashed ginkgo leaves by ethanol to obtain the ginkgo leaf extract. By adopting the extraction method, the effective component content is controlled effectively, the medicinal effect of the medicine is improved.

The invention provides a Qianlieping preparation used for treating prostatitis. The preparation comprises the following raw materials of patrinia herb, red sage root, radix paeoniae rubra, peach kernel, safflower, Japanese eupatorium, Pyrrosia lingua, frankincense, and myrrh. A preparation method of the preparation comprises the following steps: 1) weighing the raw materials; 2) crushing red sage root, radix paeoniae rubra and peach kernel, mixing the crushed material with patrinia herb, safflower, Japanese eupatorium and Pyrrosia lingua, adding a mixture in water, immersing the mixture, heating and extracting the material for 2-3 hours, filtrating the material to obtain a filtrate and filter residue; 3) adding the filter residue obtained in the step 2) in water, heating and extracting the material for 2-3 hours, filtrating the material to obtain the filtrate and filter residue; 4) adding the filter residue obtained in the step 3) in water, heating and extracting the material for 2-3 hours, filtrating the material to obtain the filtrate; and 5) merging the filtrates obtained in the step 2), the step 3) and the step 4), concentrating the material to obtain a clean paste, drying the clean paste, adding frankincense and myrrh, crushing the materials and uniformly mixing the materials. The Qianlieping preparation has the advantages of high content of effective composition, little administration amount, and high bioavailability, and is more suitable for absorption by human body.

The invention belongs to the technical field of medicine, and in particular relates to a traditional Chinese medicine extract. The traditional Chinese medicine extract comprises the following raw materials in parts by weight: 5-30 parts of vinegar cream, 30-100 parts of table vinegar and 47-119 parts of traditional Chinese medicinal materials, wherein the traditional Chinese medicinal materials include the following components in parts by weight: 4-10 parts of ginseng, 3-9 parts of aspongopus, 8-20 parts of turtle shells, 6-12 parts of glossy privet fruits, 3-10 parts of curcuma aromatica, 9-15 parts of selfheal, 5-20 parts of herb of clarke boea, 4-8 parts of fructus evodiae and 5-15 parts of liquorice. According to the traditional Chinese medicine extract provided by the invention, the table vinegar, the vinegar cream and the traditional Chinese medicinal materials are used as the raw materials; on one hand, the various raw materials themselves are rich in multiple active substanceshaving therapeutic and inhibitory effects on tumours; on the other hand, due to the synergistic effect among the table vinegar, the vinegar cream and the traditional Chinese medicinal materials, drugtherapeutic effects of the active substances in the traditional Chinese medicinal extract are effectively increased; furthermore, the table vinegar and the vinegar cream effectively reduce the toxic and side effects of the various traditional Chinese medicinal materials; and thus, the traditional Chinese medicinal extract has less toxic and side effect.

The invention relates to the technical field of traditional Chinese medicines, and in particular discloses moringa oleifera ferment for preventing and treating pneumoconiosis and a preparation method thereof. The moringa oleifera ferment is prepared from the following raw materials in percentage by weight: 1.0-3.0% of moringa oleifera leaf powder, 0.5-1.5% of licorice root, 0.5-1.5% of chrysanthemum, 0.5-1.5% of grosvener siraitia, 0.5-1.5% of European hop flower, 0.5-1.5% of boat-fruited scaphium seed, 0.1-1% of table salt, 5-15% of honey, 5-15% of fruit juice ferment and 58.5-86.4% of water. The probiotics of yeast and lactic acid bacteria in the fruit juice ferment cooperate with the moringa oleifera leaf powder to ensure that the prepared moringa oleifera ferment has a significant dust removal effect, and the medicine curative effect of traditional Chinese medicine active ingredients for resisting bacteria and diminishing inflammation is improved. The preparation method of the moringa oleifera ferment disclosed by the invention is simple and convenient to operate, and is suitable for industrial popularization and application.